Stockwatch: Stale M&A And Valuations Limit A Sector Recovery
This article was originally published in Scrip
Last week the S&P 500 and NASDAQ Biotechnology (NBI) Indexes both finished the shortened trading week up about 1.3%. On the one hand, there's nothing like a long weekend to shift investors' perspective over to the sunny side of the street. On the other, the share prices of life science stocks remain volatile and investment bank analysts are still playing catch-up with downgrades to company share price targets.
Register for our free email digests: